Literature DB >> 18852376

Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit.

Akshay Desai.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852376     DOI: 10.1161/CIRCULATIONAHA.108.807917

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  10 in total

Review 1.  Oral sodium and potassium binders in heart failure.

Authors:  Alanna A Morris; Robert T Cole; Javed Butler; Divya Gupta
Journal:  Curr Heart Fail Rep       Date:  2015-04

2.  Managing chronic diseases in the frail elderly: More than just adhering to clinical guidelines.

Authors:  Barbara Farrell; Salima Shamji; Dan Dalton
Journal:  Can Pharm J (Ott)       Date:  2014-03

Review 3.  New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?

Authors:  Anna Gromotowicz-Poplawska; Piotr Szoka; Patrycjusz Kolodziejczyk; Karol Kramkowski; Marzena Wojewodzka-Zelezniakowicz; Ewa Chabielska
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-19

4.  Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Authors:  Y Miao; D Dobre; H J Lambers Heerspink; B M Brenner; M E Cooper; H-H Parving; S Shahinfar; D Grobbee; D de Zeeuw
Journal:  Diabetologia       Date:  2010-09-30       Impact factor: 10.122

Review 5.  Hyperkalemia in patients with heart failure: incidence, prevalence, and management.

Authors:  Akshay S Desai
Journal:  Curr Heart Fail Rep       Date:  2009-12

6.  Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs.

Authors:  Esther V Uijtendaal; Jeannette E F Zwart-van Rijkom; Wouter W van Solinge; Toine C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2011-03-19       Impact factor: 2.953

7.  Noninvasive quantification of blood potassium concentration from ECG in hemodialysis patients.

Authors:  Cristiana Corsi; Marilisa Cortesi; Giulia Callisesi; Johan De Bie; Carlo Napolitano; Antonio Santoro; David Mortara; Stefano Severi
Journal:  Sci Rep       Date:  2017-02-15       Impact factor: 4.379

8.  Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker.

Authors:  Hye-Ran Jun; Hyunah Kim; Seung-Hwan Lee; Jae Hyoung Cho; Hyunyong Lee; Hyeon Woo Yim; Kun-Ho Yoon; Hun-Sung Kim
Journal:  Cardiovasc Ther       Date:  2021-01-22       Impact factor: 3.023

9.  Impact of hyperkalaemia definition on incidence assessment: implications for epidemiological research based on a large cohort study in newly diagnosed heart failure patients in primary care.

Authors:  Mar Martín-Pérez; Ana Ruigómez; Alexander Michel; Luis A García Rodríguez
Journal:  BMC Fam Pract       Date:  2016-05-04       Impact factor: 2.497

10.  Kidney Function, ACE-Inhibitor/Angiotensin Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study.

Authors:  Michael H Chiu; Robert J H Miller; Rebecca Barry; Bing Li; Bryan J Har; Stephen B Wilton; Merril Knudtson; Jonathan G Howlett; Matthew T James
Journal:  Can J Kidney Health Dis       Date:  2018-10-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.